title: [Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].
abstract: Ethinylestradiol sulphate (J 96) is a depot estrogen which in a dosage of 2 mg per week has clearly antigonadotropic effects and evokes a suppression of the free testosterone in bilaterally orchiectomized patients with carcinoma of the prostate. The good compatibility in oral application and the possibility for the controlled intake recommend its use for the long-term therapy of the carcinoma of the prostate.
mesh_terms: D002277:Carcinoma / Q000188:drug therapy*; D002369:Castration; D002986:Clinical Trials as Topic; D004028:Dienestrol / Q000008:administration & dosage; D004054:Diethylstilbestrol / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol; D004028:Dienestrol
vernacular_title: Erste Erfahrungen mit Athinylöstradiolsulfonat (J 96) bei der Therapie des Prostatakarzinoms.